PFE · 10-Q · 2026Q2

PFIZER INC

Filed 2026-08-04 · Healthcare · View original filing on EDGAR

Ranked Events

• Impairment ChargesImportance 90 · Surprise 100
  Pfizer recognized $4.325 billion of certain asset impairments in second-quarter and first-half 2026 results. The impairment charge reduced GAAP net income attributable to Pfizer common shareholders by $4.325 billion…
• Litigation and Legal RiskImportance 83 · Surprise 82
  Pfizer recorded $867 million of legal charges in second-quarter 2026 adjustments, primarily for product liability and other legal expenses. Legal charges totaled approximately $1.0 billion for the first six months of…
• Income Tax Rate ChangesImportance 71 · Surprise 82
  The second-quarter 2026 tax benefit was $407 million, compared with a tax provision in the second quarter of 2025, and the effective tax rate increased to 62.4% from 4.6%. For the first six months, the effective tax…
• Operating Cash Flow TrendsImportance 69 · Surprise 64
  Operating cash flow increased to $3.450 billion in the first six months of 2026 from $1.753 billion in the first six months of 2025. The $1.697 billion improvement was driven mainly by the timing of ordinary-course…
• Trade Policy and TariffsImportance 69 · Surprise 100
  On April 2, 2026, the U.S. Government announced Section 232 tariffs of up to 100% on imported patented pharmaceuticals and ingredients, with exemptions tied to U.S. manufacturing commitments. The measures became…
• Manufacturing Footprint OptimizationImportance 64 · Surprise 42
  Pfizer announced a new phase of its Manufacturing Optimization Program focused on network structure changes, product portfolio enhancements and operational efficiencies. The phase is expected to provide approximately…
• Headcount / RestructuringImportance 64 · Surprise 42
  Pfizer announced an additional $1.0 billion of anticipated net savings from its Realigning Our Cost Base Program, bringing expected total savings to approximately $6.7 billion through 2029. The company expects…
• Liquidity and Debt PositionImportance 59 · Surprise 48
  Pfizer reported financing cash outflows of $6.519 billion in the first six months of 2026, compared with $8.423 billion in the 2025 period. Net repayments of short-term borrowings decreased by $3.0 billion, while…
• Acquisition / Partnership / DivestitureImportance 59 · Surprise 60
  In May 2026, Pfizer entered a global licensing and collaboration agreement with Innovent, a Chinese biopharmaceutical company, covering research and development of 12 early-stage and de novo cancer medicines. Innovent…
• Patent Exclusivity ExpiriesImportance 58 · Surprise 42
  Pfizer expects a significant reduction in revenue from patent-based or regulatory exclusivity expiries as several in-line products lose exclusivity between 2026 and 2030. Management expects the rate of revenue…
• Revenue Performance and MixImportance 48 · Surprise 32
  First-six-month 2026 revenue increased 4% to $29.5 billion, with operational growth of 2%; excluding Comirnaty and Paxlovid, revenue increased 6% operationally. Growth was led by Eliquis, Padcev, the Vyndaqel family,…
• Guidance / OutlookImportance 47 · Surprise 42
  Pfizer expects leverage to remain around current levels, or modestly higher, through the next several years because of anticipated unfavorable effects from patent-based and regulatory exclusivity expiries. Management…
• Oxbryta Regulatory WithdrawalImportance 47 · Surprise 60
  After the FDA determined there was no viable pathway to return Oxbryta to the U.S. market, Pfizer voluntarily withdrew the product’s U.S. New Drug Applications on July 31, 2026. The EMA had previously concluded its…
• U.S. Tax Law ChangesImportance 47 · Surprise 60
  The U.S. One Big Beautiful Bill Act was enacted on July 4, 2025 and includes permanent expensing for domestic R&D, permanent bonus depreciation and full expensing of qualified production property. It also reduces the…
• OECD Global Minimum TaxImportance 47 · Surprise 60
  Many countries outside the U.S. have enacted global minimum-tax legislation under the OECD Base Erosion and Profit Shifting Pillar 2 project. The provisions generally apply to Pfizer from 2024, but significant…
• Competition and Market ShareImportance 46 · Surprise 56
  Prevnar family revenue declined 2% operationally year to date to $3.0 billion, primarily because of lower U.S. pediatric and adult vaccination rates and adult-indication market-share erosion, partly offset by increased…
• Geographic Revenue ShiftImportance 43 · Surprise 32
  First-six-month 2026 revenue was $17.6 billion in the U.S. and $11.9 billion internationally, compared with $17.3 billion and $11.1 billion, respectively, in the prior-year period. Eliquis growth was driven by higher…
• Manufacturing and CapacityImportance 39 · Surprise 50
  Pfizer CentreOne second-quarter 2026 revenue increased 5% operationally, driven by higher manufacturing of third-party products under manufacturing and supply agreements and higher active pharmaceutical ingredient…
• Product / Drug Pipeline ProgressImportance 38 · Surprise 60
  Pfizer reported 2026 approvals for Veppanu in ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer in the U.S.; Hympavzi for expanded hemophilia populations in the U.S. and EU; Braftovi for…
• Regulatory RiskImportance 37 · Surprise 42
  Pfizer continues to monitor U.S. implementation of the Inflation Reduction Act, including the Medicare Drug Price Negotiation Program and government-set Maximum Fair Prices. The MFP for Eliquis became effective January…

Revenue by Product (in millions)

Revenue by Geography (in millions)